Orchid Pharma schedules Q4FY26 earnings call on May 26
Orchid Pharma Limited has scheduled an analysts and investors earnings call for May 26, 2026, to review financial results for the quarter and year ended March 31, 2026. Hosted by Systematix Institutional Equities, the session will include participation from Managing Director Manish Dhanuka, Whole Time Director Mridul Dhanuka, and CFO Sunil Kumar Gupta. Dial-in details and a Diamond Pass option are available for participants.
*this image is generated using AI for illustrative purposes only.
Orchid Pharma Limited has announced the schedule for its analysts and investors earnings call to discuss the financial performance for the fourth quarter and financial year ended March 31, 2026. The conference is set to take place on Tuesday, May 26, 2026, at 4:30 PM IST. The session is being hosted by Systematix Institutional Equities.
Management Participation
The company's management team will be represented by key executives during the call. The participants include Mr. Manish Dhanuka, Managing Director; Mr. Mridul Dhanuka, Whole Time Director; and Mr. Sunil Kumar Gupta, Chief Financial Officer. They will address the financial results and answer queries from analysts and investors.
Dial-in Details
Participants can join the conference call using the dial-in numbers provided below. A Diamond Pass service is also available for connection without operator assistance.
| Location | Dial Number | Location | Toll Free Number |
|---|---|---|---|
| Primary Number | +91 22 6280 1297 | USA | 1 866 746 2133 |
| Secondary Number | +91 22 7115 8198 | UK | 0 808 101 1573 |
| Singapore | 800 101 2045 | ||
| Hong Kong | 800 964 448 |
Additional Information
The information regarding the earnings call will be hosted on the company's official website. The schedule is subject to change due to exigencies, and any modifications will be communicated accordingly. Investors can contact Systematix Institutional Equities for further details regarding the event.
Historical Stock Returns for Orchid Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.55% | +4.41% | +29.94% | -12.97% | -2.52% | -50.29% |
What key revenue growth targets or pipeline milestones is Orchid Pharma's management likely to highlight for FY2027 given the competitive generics landscape?
How might Orchid Pharma's Q4 FY2026 financial results influence analyst ratings and institutional investor sentiment toward the stock in the near term?
What strategic expansions or new drug approvals could Orchid Pharma announce following the earnings call to sustain growth momentum?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
